Ronggui Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ronggui Zhang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Chuan Xiong
Sichuan Academy of Agricultural Sciences
1 shared publication - Jianjun Li
The Second Affiliated Hospital of Chongqing Medical University
1 shared publication - Jun Zheng
State Key Laboratory of Bioreactor Engineering, Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, School of Pharmacy East China University of Science and Technology Shanghai P. R. China
1 shared publication - Junwu Li
Guangdong Medical University
1 shared publication - Junyong Zhang
Department of Urology, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China
1 shared publication - Pan Xu
Institute for Viral Hepatitis, Chongqing Medical University, Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, the Second Affiliated Hospital of Chongqing Medical University
1 shared publication
Latest Publications
- Open Access
- 5 July 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1
Publisher Correction: Pan-cancer analysis based on epigenetic modification explains the value of HJURP in the tumor microenvironment
- 5 July 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1
Open AccessPublisher Correction: Pan-cancer analysis based on epigenetic modification explains the value of HJURP in the tumor microenvironment
- Open Access
- 18 January 2021
- Published by Taylor & Francis in Bioengineered
- Vol. 12 (1) , 402-413
Puerarin induces apoptosis in prostate cancer cells via inactivation of the Keap1/Nrf2/ARE signaling pathway
In this study, we examined the antitumor effects of Puerarin (PEU) on androgen-independent (DU145 and PC-3) and androgen-dependent (LNCaP) prostate cancer cells, and explored its potential mechanisms. Supplement with PEU (2.5 μM, 5 μM, and 10 μM) exhibited a marked inhibitory effect against the growth of DU145 and PC-3 cells, especially beyond 24 h, whereas there is only slight growth inhibitory effect on LNCaP cells at the high concentration of 10 μM at 72 h. This loss of cell viability in DU145 and PC-3 cells by PEU was mediated by the induction of apoptosis via up-regulation of Bax and cleaved-caspase-3, but downregulation of Bcl-2. Moreover, more intracellular ROS and LDH production were observed in DU145 and PC-3 cells upon PEU treatment. Meanwhile, the amount of pro-inflammatory cytokines (IL-1β and IL-6) was increased, but the content of anti-inflammatory cytokines IL-10 was attenuated. Additionally, PEU pretreatment resulted in an increase of Keap1 protein expression, and a decline of Nrf2, HO-1 and NQO1 protein expression in DU145 and PC3 cells. The present findings indicated that PEU exerted its antitumor activities toward androgen-independent prostate cancer cells via inactivation of Keap1/NrF2/ARE signaling pathway. Graphical abstract
- 18 January 2021
- Published by Taylor & Francis in Bioengineered
- Vol. 12 (1) , 402-413
Open AccessPuerarin induces apoptosis in prostate cancer cells via inactivation of the Keap1/Nrf2/ARE signaling pathway
In this study, we examined the antitumor effects of Puerarin (PEU) on androgen-independent (DU145 and PC-3) and androgen-dependent (LNCaP) prostate cancer cells, and explored its potential mechanisms. Supplement with PEU (2.5 μM, 5 μM, and 10 μM) exhibited a marked inhibitory effect against the growth of DU145 and PC-3 cells, especially beyond 24 h, whereas there is only slight growth inhibitory effect on LNCaP cells at the high concentration of 10 μM at 72 h. This loss of cell viability in DU145 and PC-3 cells by PEU was mediated by the induction of apoptosis via up-regulation of Bax and cleaved-caspase-3, but downregulation of Bcl-2. Moreover, more intracellular ROS and LDH production were observed in DU145 and PC-3 cells upon PEU treatment. Meanwhile, the amount of pro-inflammatory cytokines (IL-1β and IL-6) was increased, but the content of anti-inflammatory cytokines IL-10 was attenuated. Additionally, PEU pretreatment resulted in an increase of Keap1 protein expression, and a decline of Nrf2, HO-1 and NQO1 protein expression in DU145 and PC3 cells. The present findings indicated that PEU exerted its antitumor activities toward androgen-independent prostate cancer cells via inactivation of Keap1/NrF2/ARE signaling pathway. Graphical abstract